Capricor Therapeutics (CAPR) EBIAT (2016 - 2025)
Historic EBIAT for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' EBIAT fell 9567.71% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.2 million, marking a year-over-year decrease of 10565.6%. This contributed to the annual value of -$40.5 million for FY2024, which is 8156.86% down from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' EBIAT is -$24.6 million, which was down 9567.71% from -$25.9 million recorded in Q2 2025.
- Capricor Therapeutics' EBIAT's 5-year high stood at -$762089.0 during Q4 2023, with a 5-year trough of -$25.9 million in Q2 2025.
- Its 5-year average for EBIAT is -$9.2 million, with a median of -$7.2 million in 2023.
- As far as peak fluctuations go, Capricor Therapeutics' EBIAT surged by 9012.95% in 2023, and later plummeted by 83382.83% in 2024.
- Quarter analysis of 5 years shows Capricor Therapeutics' EBIAT stood at -$6.2 million in 2021, then fell by 24.72% to -$7.7 million in 2022, then soared by 90.13% to -$762089.0 in 2023, then crashed by 833.83% to -$7.1 million in 2024, then plummeted by 245.26% to -$24.6 million in 2025.
- Its EBIAT stands at -$24.6 million for Q3 2025, versus -$25.9 million for Q2 2025 and -$7.1 million for Q4 2024.